# Checkmate Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/checkmate-therapeutics-co

- Industry: Healthcare Specialists
- Headquarters: Seoul, South Korea
- Website: www.checkmatetx.com
- Total disclosed funding: $6.6M
- Latest round: Series A (Nov 12, 2020)
- Investors on record: 3

## About

Checkmate Therapeutics, based in Seoul, South Korea, focuses on developing innovative therapeutics aimed at treating cancer and other incurable diseases, enhancing patient outcomes through targeted treatments.Checkmate Therapeutics is dedicated to advancing treatment options for cancer. Founded in 2019 in Seoul, South Korea by Hyunseok Kim, the company raised KRW 7.3 billion in Series A funding on November 12, 2020, from investors including KB Investment, Partners Investment, and Quad Asset Management. The company has executed one deal to date.Checkmate Therapeutics specializes in developing innovative therapeutics for cancer and other incurable diseases. Their core offerings focus on breakthrough medicines targeted to improve patient outcomes and quality of life. The company’s therapeutics are tailored for various cancer types, addressing specific disease mechanisms. Their client base includes hospitals, oncology clinics, and research institutions in North America and Europe, supported by a robust drug pipeline undergoing clinical evaluations.Checkmate Therapeutics generates revenue primarily through partnerships with healthcare providers and research institutions, engaging in B2B transactions to supply its therapeutics. Structured agreements facilitate the purchase of patented treatments under specific pricing plans, ensuring hospitals and clinics access the latest innovations in oncology. These arrangements include both direct sales and collaborative research initiatives, forming a steady revenue stream for the company.Checkmate Therapeutics plans to leverage the KRW 7.3 billion raised in Series A funding to enhance its product pipeline and expand into new markets. The funding will support ongoing clinical trials and the development of new therapeutics aimed at various cancer types. The company intends to target expansion into additional geographic regions, particularly in North America and Europe, by 2023. These efforts are aimed at strengthening their market position and improving access to their innovative therapies.

## Funding rounds

- Series A, Nov 12, 2020, $6.6M — KB Investment, Partners Investment, Quad Asset Management

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series A
- Quad Asset Management — Series A